Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
January 14, 2026Pamplona/MadridIn recruitment
-
January 14, 2026Pamplona/MadridIn recruitment
-
January 12, 2026PamplonaIn recruitment
-
January 5, 2026Pamplona/MadridIn recruitment
-
January 5, 2026Pamplona/MadridIn recruitmentEarly phase
MEDOPP485 Clinical trial to evaluate the efficacy of treatments by controlling minimal residual disease in a population with early breast cancer.
The main objective is to evaluate the efficacy, in terms of the percentage of patients with a 90% reduction or elimination of baseline ctDNA after three months, of the different groups. -
December 16, 2025Pamplona/MadridIn recruitment
-
November 24, 2025Pamplona/MadridIn recruitment
NOVOFFOX Trial of tumor treatment fields (TTFields, 150 kHz) concomitant with modFOLFIRINOX for the first-line treatment of metastatic pancreatic adenocarcinoma (NOVOFFOX).
The aim of this study is to evaluate the efficacy and safety of TTFields in combination with the chemotherapy you will receive for your cancer (oxaliplatin-irinotecan-fluorouracil, FOLFIRINOX). -
November 19, 2025Pamplona/MadridIn recruitment
M22-132 Ensayo de Epcoritamab en combinación con antineoplásicos en pacientes con linfoma no Hodgkin [SP]
The purpose of this study is to evaluate a drug called Epcoritamab in combination with other drugs used to treat non-Hodgkin lymphoma (NHL). Epcoritamab may work better when combined with other drugs that treat cancer in different ways. -
November 19, 2025Pamplona/MadridIn recruitment
-
November 19, 2025Pamplona/MadridIn recruitment
MK-2870-004 Randomized, open-label, phase 3 clinical trial of MK-2870 in previously treated non-small cell lung cancer with EGFR mutations or other genomic alterations.
El objetivo principal de este estuido es comparar MK-2870 con la quimioterapia con respecto a la SLP según RECIST 1.1 evaluada por evaluada por BICR en CPNM con mutaciones del EGFR mutaciones.